Inflammatory bowel disease in pregnancy and breastfeeding
10.1038/s41575-023-00758-3 · doi-reference
Transabdominal redo ileal pouch surgery for failed restorative proctocolectomy: lessons learned over 500 patients
10.1097/sla.0000000000001386 · doi-reference
Thoughtful ileostomy creation in patients undergoing redo IPAA
10.1097/dcr.0000000000001535 · doi-reference
Fertility is reduced after restorative proctocolectomy with ileal pouch anal anastomosis: a study of 300 patients
10.1016/j.surg.2004.06.018 · doi-reference
The pouch corner: perianal fistulas and ileal pouches: examining fistulas before and after pouch creation
10.1093/ibd/izae205 · doi-reference
Proctocolectomy without ileostomy for ulcerative colitis
10.1136/bmj.2.6130.85 · doi-reference
Restorative pouch surgery following proctocolectomy for inflammatory bowel disease: past experience and future direction
10.21037/tgh-23-28 · doi-reference
Crohn’s disease of the esophagus, duodenum, and stomach
10.1055/s-0039-1683850 · doi-reference
Strictureplasty in complex Crohn’s disease: beyond the basics
10.1055/s-0039-1683905 · doi-reference
Recurrence of Crohn’s disease after ileocolic resection is not affected by anastomotic type: results of a multicenter, randomized, controlled trial
10.1007/dcr.0b013e3181a4fa58 · doi-reference
Surgical recurrence at anastomotic site after bowel resection in Crohn’s disease: comparison of Kono-S and end-to-end anastomosis
10.1007/s11605-018-4012-6 · doi-reference
Kono-S anastomosis for surgical prophylaxis of anastomotic recurrence in crohn’s disease: an international multicenter study
10.1007/s11605-015-3061-3 · doi-reference
Novel antimesenteric functional end-to-end handsewn (Kono-S) anastomoses for Crohn’s disease: a report of surgical procedure and short-term outcomes
10.1159/000371857 · doi-reference
Effect of mesenteric sparing or extended resection in primary ileocolic resection for Crohn’s disease on postoperative endoscopic recurrence (SPICY): an international, randomised controlled trial
10.1016/s2468-1253(24)00097-9 · doi-reference
Inclusion of the mesentery in ileocolic resection for Crohn’s disease is associated with reduced surgical recurrence
10.1093/ecco-jcc/jjx187 · doi-reference
Effect of resection margins on the recurrence of Crohn’s disease in the small bowel. A randomized controlled trial
10.1097/00000658-199610000-00014 · doi-reference
Restorative proctocolectomy: an example of how surgery evolves in response to paradigm shifts in care
10.1111/codi.13699 · doi-reference
Early ileocecal resection for Crohn’s disease is associated with improved long-term outcomes compared with anti-tumor necrosis factor therapy: a population-based cohort study
10.1053/j.gastro.2023.05.051 · doi-reference
Rates of intestinal resection and colectomy in inflammatory bowel disease patients after initiation of biologics: a cohort study
10.1016/j.cgh.2020.10.008 · doi-reference
The role of laparoscopic, robotic, and open surgery in uncomplicated and complicated inflammatory bowel disease
10.1016/j.giec.2019.02.012 · doi-reference
Vedolizumab, adalimumab, and methotrexate combination therapy in Crohn’s disease (EXPLORER)
10.1016/j.cgh.2023.09.010 · doi-reference
Safety and tolerability of concurrent natalizumab treatment for patients with Crohn’s disease not in remission while receiving infliximab
10.1002/ibd.20014 · doi-reference
Dual-targeted therapy with upadacitinib and ustekinumab in medically complex Crohn’s disease
10.1007/s10620-023-08182-y · doi-reference
Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial
10.1016/s2468-1253(22)00427-7 · doi-reference
Current evidence for combined targeted therapy for the treatment of inflammatory bowel disease
10.1093/jcag/gwad032 · doi-reference
Dual biologic therapy induces remission in refractory Crohn’s disease with vedolizumab and ustekinumab
10.1093/crocol/otae080 · doi-reference
Effectiveness and safety of advanced combination treatment in patients with refractory inflammatory bowel disease or concomitant immune-mediated disease or extraintestinal manifestations: a multicenter Canadian study
10.14309/ajg.0000000000003573 · doi-reference
Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies
10.1016/s0140-6736(23)00061-2 · doi-reference
Ozanimod as induction and maintenance therapy for ulcerative colitis
10.1056/nejmoa2033617 · doi-reference
Efficacy and safety of S1P1 receptor modulator drugs for patients with moderate-to-severe ulcerative colitis
10.3390/jcm12155014 · doi-reference
Upadacitinib induction and maintenance therapy for Crohn’s disease
10.1056/nejmoa2212728 · doi-reference
Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials
10.1016/s0140-6736(22)00581-5 · doi-reference
Tofacitinib in the treatment of ulcerative colitis: efficacy and safety from clinical trials to real-world experience
10.1177/1756284819848631 · doi-reference
Tofacitinib as induction and maintenance therapy for ulcerative colitis
10.1056/nejmoa1606910 · doi-reference
The JAK/STAT signaling pathway: from bench to clinic
10.1038/s41392-021-00791-1 · doi-reference
Biologics vs small molecules: drug costs and patient access
10.1016/j.medidd.2020.100075 · doi-reference
Vedolizumab and anti-tumour necrosis factor α real-world outcomes in biologic-naïve inflammatory bowel disease patients: results from the EVOLVE study
10.1093/ecco-jcc/jjab058 · doi-reference
Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn’s disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial
10.1016/s0140-6736(22)00688-2 · doi-reference
Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis
10.1056/nejmoa1905725 · doi-reference
Efficacy and safety of subcutaneous guselkumab induction therapy in patients with moderately to severely active Crohn’s disease: results through week 48 from the phase 3 GRAVITI study
10.14309/01.ajg.0001033576.85427.3d · doi-reference
